Statement re: Appointment of Corporate Broker



Appointment of Corporate Broker

The Board of DXS International plc (“the Company”), the NEX Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce the appointment of Hybridan LLP as Corporate Broker to the Company with immediate effect. 

David Immelman (Chief Executive) commented:

"NEX is for now the platform for DXS International plc to achieve its ambitious growth plans over the coming year. DXS is delighted to have signed with Hybridan, a NEX and AIM Broker who will act as our Corporate Broker for the next phase of our journey.”

The Directors of DXS International plc accept responsibility for this announcement.


David Immelman   (Chief Executive)
DXS International plc
01252 719800  

Corporate Advisor

City & Merchant
David Papworth

020 7101 7676


Corporate Broker

Hybridan LLP
Claire Noyce

020 3764 2341


Note to Editors:

About DXS

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.